Cover Image
Market Research Report

KOL Perspectives: JAK Inhibitor Safety in IBD

Published by GlobalData Product code 721705
Published Content info 31 Pages
Delivery time: 1-2 business days
Price
Back to Top
KOL Perspectives: JAK Inhibitor Safety in IBD
Published: May 1, 2018 Content info: 31 Pages
Description

This KOL Insight briefing focuses on the potential use of selective JAK inhibitors in IBD.

The briefing includes analysis of KOL opinion on the following topic areas -

  • Maintenance data for selective JAKs in Crohn's disease
  • Differentiating strategies for selective and non-selective JAKs in IBD
  • Choice of primary endpoints for IBD trials
  • Selective JAKs' expected efficacy in UC
  • Real-world use of JAKs in IBD

Key Highlights

  • KOLs are broadly positive about TOF's safety profile in UC, highlighting TOF's relative comparability to safety seen in other indications
  • Most KOLs view the majority of JAK inhibitors in development in IBD as has having similar safety profiles, regardless of JAK-selectivity
  • Most KOLs agree that patients should ideally be vaccinated before immunosuppressant treatment, however, reimbursement remains a significant barrier that can restrict vaccination to during treatment.

Scope

  • The insight briefing is based on Sociable Pharma's analysis of primary research with our 10 key opinion leaders (KOLs)
  • In total, we conducted interviews with 10 KOLs: 5 Europe-based & 5 US-based
  • Interviews performed during March 2018
  • KOL data is analyzed to produce: Charts summarizing KOL opinions
  • Chart call-outs of key information & details
  • KOL quotes
  • Summary of KOL reporting trends
  • Insight from Sociable Pharma's analysts.

Reasons to buy

  • Combines Qualitative & semi-quantitative insight from key opinion leaders on "JAK Inhibitor Safety in IBD"
  • Includes insight & recommendations from our disease-specific healthcare analysts
  • Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of IBD
  • Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.
Table of Contents
Product Code: GDHC012SP

Table of Contents

  • Executive Summary
  • Background
  • Research Panel Composition
  • Results & Implications

Appendix

Back to Top